Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong
· Delayed Price · Currency is HKD 38.95
+1.25 (3.32%)
Apr 24, 2025, 4:08 PM HKT
Shanghai Henlius Biotech Revenue
In the year 2024, Shanghai Henlius Biotech had annual revenue of 5.72B CNY with 6.11% growth. Shanghai Henlius Biotech had revenue of 2.98B in the half year ending December 31, 2024, with 54.69% growth.
Revenue
5.72B CNY
Revenue Growth
+6.11%
P/S Ratio
3.36
Revenue / Employee
1.63M CNY
Employees
3,515
Market Cap
20.49B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 29.60B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| Innovent Biologics | 10.03B |
| Akeso | 2.26B |
| Alibaba Health Information Technology | 31.39B |
| Sino Biopharmaceutical | 30.72B |